Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 7NIH 5INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Hepatocellular 79Carcinoma, Renal Cell 36Neoplasms 35Liver Neoplasms 22Carcinoma, Non-Small-Cell Lung 7Carcinoma 7Neoplasm Metastasis 6Melanoma 5Thyroid Neoplasms 4Kidney Neoplasms 4Breast Neoplasms 3Financial Stress 2Vaccinia 1Stomach Neoplasms 1Patient Preference 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Lymphoma 1Lung Neoplasms 1Liver Diseases 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Insulin-Like Growth Factor I, Resistance To 1Hypophosphatemia 1Hepatitis C 1Hepatitis B 1Glioblastoma 1Digestive System Neoplasms 1

Interventions

Temozolomide 94Radiotherapy 40Bevacizumab 40Lomustine 21Radiation 18Surgical Procedures, Operative 10Carboplatin 9pembrolizumab 8Nivolumab 8Carmustine 8Irinotecan 7IL13-PE38 6Granulocyte-Macrophage Colony-Stimulating Factor 6Flucytosine 6Cyclophosphamide 6ABT-414 6vocimagene amiretrorepvec 5depatuxizumab mafodotin 5Valacyclovir 5Drug Therapy 5veledimex 4sargramostim 4enzastaurin 4NVP-BKM120 4Gemcitabine 4Dianhydrogalactitol 4Chlorotoxin 4Aminolevulinic Acid 4verubulin 3selinexor 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Glioblastoma × Sorafenib × Clear all
NCT01441388 2011-12-20

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

Pfizer

Phase 1 Withdrawn
CNSGastrointestinalGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡